Joint Pain Injections Market Research, 2031
The global joint pain injections market size was valued at $6,271.91 million in 2021, and is projected to reach $13,176.31 million by 2031, growing at a CAGR of 7.7% from 2022 to 2031. Joint pain injections are administered directly into the joints to relieve pain and minimize the inflammation and swelling. Joint pain usually occurs in the geriatric population as a result of pre-existing illnesses or diseases. Arthritis is the common condition that basically occurs in the knee & ankle joint, hip joint, shoulder & elbow, and facet joints of the spine leads to the joint pain that cause inflammation and contribute to joint discomfort. Furthermore, rise in prevalence of osteoarthritis and rheumatoid arthritis and increase in need for affordable treatments for such conditions are expected to expand during the joint pain injections market forecast.
Get more information on this report
According to the Arthritis Research UK report, “The State of Musculoskeletal Health 2018”, it is estimated that 17.8 million people suffer with a musculoskeletal condition in the UK which is around 28.9% of the total population of the country. Thus, this highlights the need for the joint pain injections to manage and prevent the pain associated with several diseases.
Rise in elderly population and high prevalence of the obese population boost the demand for the treatment options for joint pain. To overcome this increasing demand, the key market players are carrying out research and development activities to invent more efficient treatment options which includes the single injection therapy, platelet-rich plasma, prolotherapy, autologous conditioned serum and plasma matrix therapy. Furthermore, platelet-rich plasma (PRP) is made from the patient’s own blood, which is then injected into painful joint which relieves the pain and stiffness in arthritis. Thus, development of such advanced techniques provides opportunities to the key market players for investment, which will further drive the growth of the market during the forecast period.
Nowadays, there has been increase in incidence rate of injuries due to accidents, which is the key factor that contributes toward the growth of the joint pain injections market size. For instance, according to National Highway Traffic Safety Administration (NHTSA), a noticeable increase of 10.5% fatalities in year 2021 in the U.S was reported. Thus, rise in prevalence of accidental injuries leads to the incidences of joint pain, and causes surge in demand for joint pain injections, which drives the growth of the joint pain injections market share.
In addition, the growth in the number of arthritis cases along with the rise in joint disorders, rise in the number of geriatric patients and prevalence of the obesity worldwide are the drivers that are causing the expansion of the joint pain injections market, on the other hand increasing R&D initiatives by the key market players and advances such as single injection therapy and plasma matrix therapy, will provide lucrative opportunities for the market players to invest and lead to the market growth. However, the strict regulatory standards, and expensive development and purchase costs can provide a hindrance to the market growth in the near future.
Impact of COVID-19 on Joint Pain Injections Market
The COVID-19 pandemic have proved to be an incomparable global public health emergency that has affected almost every industry, and the effects are expected to impact every industry growth during the forecast period. Several changes in consumer demand and behavior, buying habits, supply chain redirection, and significant government initiatives have been seen around the globe. The COVID-19 pandemic has changed the living pattern, other substance use and other health-related behaviors of the population. Additionally, COVID-19 registered decline in sales of the joint pain injections, thereby restraining the market growth during the pandemic. Many key market players registered the decrease in their revenues from the joint pain injection segments, which was mainly due to decline in the patient visit to the hospitals, reallocation of the healthcare resources and effect on the supply chain around the globe.
The joint pain injections market is segmented into Injection Type, Joint Type and Distribution Channel.
The global joint pain injections market is segmented by injection type, joint type, distribution channel, and region. On the basis of injection type, the market is categorized into interleukin inhibitors, hyaluronic acid injections and others. By joint type, it is divided into knee & ankle, hip joint, shoulder & elbow, facet joints of the spine and others. By distribution channel, it is segmented into hospital pharmacies, drug stores and retail pharmacies, and online providers. Hospital pharmacies are further divided into public hospital pharmacies and private hospital pharmacies. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Segment Review
By Injection Type
Others segment held a dominant position in 2021 and would continue to maintain the lead over the forecast period.
By injection type, the market is segmented into interleukin inhibitors, hyaluronic acid injections and others. The others segment generated maximum revenue in 2021, aiding to the awareness about the use of new advanced technologies such as placental tissue matrix (PTM) injections, epidural in the treatment of different kinds of arthritis. Moreover, the hyaluronic acid injections segment is expected to expand at a higher CAGR during the forecast, due to the large number of product launches involving the hyaluronic acid injections and awareness about hyaluronic acid as the treatment option.
By Joint Type
Knee and Ankle segment is projected as one of the most lucrative segment.
Depending on the joint type, the market is divided into knee & ankle, hip joint, shoulder & elbow, facet joints of the spine and others. The knee and ankle segment dominated the market in 2021, whereas the hip joint segment is expected to grow with a highest CAGR, owing to the rise in the number of accidents and injuries related to the accidents leading to the hip joint pain and rise in the number of geriatric patients.
By Distribution Channel
Drug Stores and Retail Pharmacies segment is projected as one of the most lucrative segment.
Depending on distribution channel, the market is divided into hospital pharmacies, drug stores and retail pharmacies, and online providers. The drug stores and retail pharmacies segment dominated the market in 2021 and the online providers is expected to grow with highest CAGR owing to surge in the demand for joint pain solutions, digitalization, adoption of smartphones and smart devices and easy accessibility.
By Region
North America held a dominant position in 2021 and would continue to maintain the lead over the forecast period.
Region wise, North America acquired a major joint pain injections market share in the year 2021, owing to the presence of key players, rising government initiatives, well-developed healthcare infrastructure, and rising prevalence of joint disorders. The region witnessed the highest CAGR. However, Asia-Pacific is expected to witness the highest growth rate for the joint pain injections industry during the forecast period with a highest CAGR.The major factors that drive the growth of the joint pain injections market in this region are rise in geriatric populations, increase in prevalence of obesity causing joint pain, advancements in solutions, and increase in government initiatives to promote healthy lifestyle are driving the joint pain injections market Growth.
The major companies profiled in this joint pain injections industry report include Abbvie Inc., Anika Therapeutics Inc., Bioventus Inc., Eli Lilly and Company, Ferring Pharmaceuticals Inc., Pacira Biosciences (Flexion Therapeutics, Inc.), Pfizer Inc., Sanofi S.A., Teva Pharmaceuticals, Zimmer Biomet and among others.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the joint pain injections market analysis from 2021 to 2031 to identify the prevailing joint pain injections market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the joint pain injections market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global joint pain injections market trends, key players, market segments, application areas, and market growth strategies.
Joint Pain Injections Market Report Highlights
| Aspects | Details |
 Market Size By 2031 | USD 13.2 billion |
 Growth Rate | CAGR of 7.7% |
 Forecast period | 2021 - 2031 |
 Report Pages | 310 |
 By Joint Type |
|
 By Distribution Channel |
|
 By Injection Type |
|
 By Region |
|
 Key Market Players | Eli Lilly and Company, AbbVie Inc, Anika Therapeutics Inc., Sanofi S.A., Teva Pharmaceuticals, Pfizer Inc., Ferring Pharmaceuticals Inc., Bioventus, PACIRA BIOSCIENCES (Flexion Therapeutics, Inc.) |
Analyst Review
This section provides various opinions of top-level CXOs in the joint pain injection market. The joint pain injections market has piqued the interest of healthcare providers, patients, and consumers, owing to several benefits offered by these products, which helps to relieve the pain associated with the various bone and muscle related disorders. There have been remarkable advancements in development of joint pain injections to provide advanced options for the treatment. As the market is saturated and is growing at a steady rate in developed nations, Asia-Pacific and LAMEA are expected to offer high growth opportunities to key players in this market.
According to the perspectives of CXOs of leading companies in the market, significant advancements in the products for treating joint pain, along with increase in clinically backed research, growth in investments, funds, and grants, increasing incidence of target diseases, entry of new players, and growth in the geriatric population is projected to increase the sale of joint pain injections globally. Presently, rapid adoption of these products due to rise in the number of sports and fitness injuries is also accelerating the growth of the market.
Rise in investment for research and development of the advanced and precise treatment options by public and private players in the market with an aim to improve health care infrastructure, due to the rise in the prevalence of the arthritis, along with rise in the obesity and geriatric patients are the upcoming trends of Joint Pain Injections Market.
Joint pain is the leading application of Joint Pain Injections Market.
North America is the largest regional market for Joint Pain Injections.
Joint Pain Injections Market is projected to reach $13,176.31 million by 2031, registering a CAGR of 7.7% from 2022 to 2031.
The major companies profiled in this report include Abbvie Inc., Anika Therapeutics Inc., Bioventus Inc., Eli Lilly and Company, Ferring Pharmaceuticals Inc., Pacira Biosciences (Flexion Therapeutics, Inc.), Pfizer Inc., Sanofi S.A., Teva Pharmaceuticals, Zimmer Biomet and among others.
The base year is 2021 in Joint Pain Injections market.
Yes, the Joint Pain Injections market report provides PORTER Analysis.
Loading Table Of Content...
Loading Research Methodology...
